drugset / Trial / NCT00427934

Maraviroc in Rheumatoid Arthritis

NCT00427934

Phase 2 Terminated 128 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate whether maraviroc, an investigational drug given with methotrexate (MTX) is safe and effective in the treatment of rheumatoid arthritis in adult patients.

Timeline

Start
2007-02
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Maraviroc Other / unclassified 150 mg Oral
Subject Maraviroc Other / unclassified 300 mg Oral

Indications